The importance of the World Symposium on Pulmonary Hypertension

Jardim, Carlos; Waetge, Daniel

doi:10.1590/s1806-37562018000030001

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between pulmonary diseases and PH was thus formally established and assigned the third group in the classification. Dana Point Classification was given during the 4 th symposium and the treatment algorithm updated [ 2 , 3 ]. In 2018, the 6 th World Symposium on Pulmonary Hypertension was a landmark as a proposal was made to revise hemodynamic definition and set mPAP threshold at a lower value to ≥20 mmHg [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions

Tyagi

Kant

Pradhan

et al. 2021

Canadian Respiratory Journal

View full text Add to dashboard Cite

Background. Pulmonary hypertension is a dreaded disease associated with considerable morbidity and mortality. The pulmonary hypertension developing due to chronic respiratory disease is a unique subset with symptoms often getting masqueraded by the underlying respiratory condition. The importance of early detection of this complication has been realized worldwide, and recently, the definition of pulmonary hypertension was revised to set the cutoff of mean pulmonary artery pressure (mPAP) at 20 mmHg instead of 25 mmHg at rest. In our study, we have tried to estimate the difference this new definition brings to the prevalence of pulmonary hypertension among interstitial lung disease patients at our centre. Methods. This was a cross-sectional study in which all the patients of ILDs (n = 239) attending the outdoor and indoor Department of Respiratory Medicine, King George’s Medical University, India, for the duration of one year were subjected to transthoracic echocardiography along with measurement of serum pro-B-type natriuretic peptide (BNP) and troponin T values. The data were analyzed using the different definitions, and the prevalence was compared. Result. Incidence of pulmonary hypertension among ILD patients at mPAP cutoff ≥ 25 was 28.9%, while that at value ≥20 mmHg, incidence of pulmonary hypertension increased to 46.0%. An increment of 15–20% in incidence of pulmonary hypertension was observed among different types of ILD when cutoff of mPAP was changed. Conclusion. The new definition helps in a significant increase in the detection of pulmonary hypertension, which certainly helps in earlier detection and better management of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions

Tyagi

Kant

Pradhan

et al. 2021

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension

Charoenpong,

Hall,

Keller

et al. 2024

CHEST

View full text Add to dashboard Cite

Shifting Paradigms in the Management of Pulmonary Hypertension

Pradhan,

Tyagi,

Sharma

et al. 2024

Eur Cardiol

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in <3 years. Over the past decade, many advances have been made in revising the haemodynamic definition, clinical classification, risk calculation score, treatment options etc. Suggestions from the Sixth World Symposium on Pulmonary Hypertension were incorporated into a literature review that was included in the European Society of Cardiology/European Respiratory Society (ESC/ERS)’s most recent iteration of their guidelines in 2022. The traditional cut-off for pulmonary hypertension (PH), i.e., mean pulmonary artery pressure (mPAP) >25 mm Hg, has been challenged by observational cohort studies, which have shown poor outcomes for values of 21–24 mmHg; the new consensus is that PH is defined at mPAP >20 mm Hg. Although the gold standard for diagnosis and the major source of therapy guidance continues to be right cardiac catheterisation, echocardiography remains the initial test of choice. A multidisciplinary approach is highly recommended when treating PH patients and careful evaluation of patients will aid in proper diagnosis and prognosis. Pharmacotherapy for PAH has seen a paradigm shift with the successful use of newer agents in more extensive, longer and more inclusive trials driven by hard endpoints. Macitentan, selexipag and riociguat are three oral agents that have shown astounding success in PAH randomised studies in the past decade. Upfront combination therapy with two agents is now becoming the norm (following the AMBITION, OPTIMA and ITALY trials) and the momentum is shifting towards triple therapy as for essential hypertension. More recently, inhaled treprostinil was shown to improve exercise capacity in PH associated with interstitial lung disease in the phase III INCREASE study and has been granted regulatory approval for World Health Organization group 3 PH. A new class of drug, sotatercept (a tumour growth factor-β signalling inhibitor), has also been recently approved by the Food and Drugs Administration for management of PAH based on positive results from the phase III STELLAR study. Pulmonary artery denervation and balloon pulmonary angioplasty have emerged as viable alternatives in PH that are resistant to drug therapy. This article aims to summarise the key changes and recent advances in diagnosis and managing PH in general, with an emphasis on certain subgroups.

show abstract

The importance of the World Symposium on Pulmonary Hypertension

Cited by 5 publications

References 13 publications

Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions

Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions

Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension

Shifting Paradigms in the Management of Pulmonary Hypertension

Contact Info

Product

Resources

About